Pancreatic Cancer Research

ResearcherKanazawa UniversityActive in the last 2 years

Tetsuo Ohta

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1965-2864; OpenAlex author ID A5045381404, A5109830939. Sources: OpenAlex.

Their work

Papers
26 (first author 3, last author 11)
Trials
0
Grants
0
Labs led
2
Collaborators
42
Papers, trials and grants by year

2011: 1 paper · 2012: 3 papers · 2013: 4 papers · 2014: 3 papers · 2015: 1 paper · 2016: none · 2017: 3 papers · 2018: 3 papers · 2019: 2 papers · 2020: none · 2021: 2 papers · 2022: 2 papers · 2023: none · 2024: 2 papers

Papers 26

  1. Morphology of the Dorsal Pancreatic Artery and Its Oncological Significance in Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000002327↗
  2. Enhanced Germinal Center Reactions Within Tertiary Lymphoid Structures Following Neoadjuvant Chemotherapy and Intestinal Care-A Path to Robust Antitumor Immune… Co-author PMID 39571990↗
  3. Verification of Resectability Status for Pancreatic Cancer: Radiological and Pathological Analysis of Patients Undergoing Pancreatoduodenectomy With Combined R… Last author DOI 10.1097/mpa.0000000000001964↗
  4. [A case of incipient pancreatic ductal adenocarcinoma concomitant with intraductal papillary mucinous neoplasm, confirmed by multiregion sequencing analysis]. Co-author DOI 10.11405/nisshoshi.119.368↗
  5. A phase I study of preoperative (neoadjuvant) chemotherapy with gemcitabine plus nab-paclitaxel for resectable pancreatic cancer. Last author DOI 10.3892/mco.2020.2188↗
  6. [Intestinal Care Using L‒Glutamine Supplement and Probiotics Can Induce a Strong Anti‒Tumor Immune Response through the Induction of Mature Tertiary Lymphoid S… Co-author PMID 33976027↗
  7. Clinical Impact of Neoadjuvant Chemotherapy and Chemoradiotherapy in Borderline Resectable Pancreatic Cancer: Analysis of 884 Patients at Facilities Specializi… Co-author DOI 10.1245/s10434-018-07131-8↗
  8. Impact of Extravasated Platelet Activation and Podoplanin-positive Cancer-associated Fibroblasts in Pancreatic Cancer Stroma. Last author DOI 10.21873/anticanres.13750↗
  9. Contribution of equilibrative nucleoside transporters 1 and 2 to gemcitabine uptake in pancreatic cancer cells. Co-author DOI 10.1002/bdd.2131↗
  10. Phase I study of third-line palliative chemotherapy with low dose paclitaxel for pancreatic cancer. Last author DOI 10.3892/mco.2018.1579↗
  11. [A Case of Pathological Complete Response Induced by Preoperative Chemotherapy with Gemcitabine plus Nab-Paclitaxel in a Patient with Pancreatic Cancer on Hemo… Last author PMID 30692318↗
  12. Low-dose gemcitabine induces major histocompatibility complex class I-related chain A/B expression and enhances an antitumor innate immune response in pancreat… Last author DOI 10.1007/s10238-015-0394-x↗
  13. Clinical features of cystatin A expression in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/cas.13396↗
  14. Neoadjuvant chemotherapy for pancreatic cancer: Effects on cancer tissue and novel perspectives. Last author DOI 10.3892/ol.2017.6008↗
  15. Inflammatory features of pancreatic cancer highlighted by monocytes/macrophages and CD4+ T cells with clinical impact. Co-author DOI 10.1111/cas.12663↗
  16. Expression of Akt kinase-interacting protein 1, a scaffold protein of the PI3K/PDK1/Akt pathway, in pancreatic cancer. Co-author DOI 10.1097/mpa.0000000000000168↗
  17. Pioglitazone inhibits the proliferation and metastasis of human pancreatic cancer cells. Last author DOI 10.3892/ol.2014.2553↗
  18. [A case report of hepatic arterial infusion chemotherapy and RFA for liver metastasis from pancreatic cancer]. Last author PMID 25731471↗
  19. A phase I study of neoadjuvant chemotherapy with gemcitabine plus oral S-1 for resectable pancreatic cancer. Last author DOI 10.3892/mco.2013.133↗
  20. Hepatic arterial infusion chemotherapy with gemcitabine and 5-fluorouracil or oral S-1 improves the prognosis of patients with postoperative liver metastases f… Co-author DOI 10.3892/mco.2013.152↗
  21. [Gemcitabine augments major histocompatibility complex class I-related chain A expression in pancreatic cancer]. Last author PMID 24393861↗
  22. [Hepatic arterial infusion chemotherapy with gemcitabine for patients with postoperative liver metastases from pancreatic cancer]. Co-author PMID 24393883↗
  23. Pilot study of neoadjuvant chemotherapy with gemcitabine and oral S-1 for resectable pancreatic cancer. First author DOI 10.3892/etm.2012.482↗
  24. Neoadjuvant chemotherapy with gemcitabine for pancreatic cancer increases in situ expression of the apoptosis marker M30 and stem cell marker CD44. First author DOI 10.3892/ol.2012.657↗
  25. Increased E-selectin in hepatic ischemia-reperfusion injury mediates liver metastasis of pancreatic cancer. Co-author DOI 10.3892/or.2012.1896↗
  26. Pilot study of hepatic arterial infusion chemotherapy with gemcitabine and 5-fluorouracil for patients with postoperative liver metastases from pancreatic canc… First author DOI 10.3892/etm.2011.190↗

Closest collaborators

The 25 strongest of 42 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Isamu Makino · 19 shared papers, 2011–2024 · strength 1.49
  2. Mitsuyoshi Okazaki · 8 shared papers, 2018–2024 · strength 1.12
  3. Hidehiro Tajima · 19 shared papers, 2011–2022 · strength 1.09
  4. Tomoharu Miyashita · 12 shared papers, 2013–2021 · strength 0.76
  5. Itasu Ninomiya · 12 shared papers, 2011–2022 · strength 0.61
  6. Shintaro Yagi · 2 shared papers, 2024 · strength 0.51
  7. Takahiro Kyuno · 1 shared paper, 2024 · strength 0.20
  8. Satoshi Takada · 1 shared paper, 2024 · strength 0.20
  9. Masahiro Sato · 1 shared paper, 2022 · strength 0.16
  10. Shinya Tanaka · 1 shared paper, 2022 · strength 0.16
  11. Yusuke Mizukami · 1 shared paper, 2022 · strength 0.16
  12. Yoshimichi Sai · 3 shared papers, 2013–2018 · strength 0.12
  13. Takuya Komura · 2 shared papers, 2015–2017 · strength 0.11
  14. Shuichi Kaneko · 2 shared papers, 2015–2017 · strength 0.11
  15. Yoshio Sakai · 2 shared papers, 2015–2017 · strength 0.11
  16. Yuichi Hosokawa · 1 shared paper, 2019 · strength 0.07
  17. Yoshiaki Murakami · 1 shared paper, 2019 · strength 0.07
  18. Sohei Satoi · 1 shared paper, 2019 · strength 0.07
  19. Shuji Isaji · 1 shared paper, 2019 · strength 0.07
  20. Shigeyuki Kawachi · 1 shared paper, 2019 · strength 0.07
  21. Masayuki Sho · 1 shared paper, 2019 · strength 0.07
  22. Hiroki Yamaue · 1 shared paper, 2019 · strength 0.07
  23. Yuichi Nagakawa · 1 shared paper, 2019 · strength 0.07
  24. Shuji Suzuki · 1 shared paper, 2019 · strength 0.07
  25. Akihiko Tsuchida · 1 shared paper, 2019 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.